GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Inventory Turnover

Amryt Pharma (Amryt Pharma) Inventory Turnover : 0.31 (As of Sep. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Amryt Pharma's Cost of Goods Sold for the three months ended in Sep. 2022 was $33.7 Mil. Amryt Pharma's Average Total Inventories for the quarter that ended in Sep. 2022 was $107.2 Mil. Amryt Pharma's Inventory Turnover for the quarter that ended in Sep. 2022 was 0.31.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Amryt Pharma's Days Inventory for the three months ended in Sep. 2022 was 290.27.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Amryt Pharma's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 1.75.


Amryt Pharma Inventory Turnover Historical Data

The historical data trend for Amryt Pharma's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Inventory Turnover Chart

Amryt Pharma Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.11 3.65 1.29 2.40 1.35

Amryt Pharma Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.27 0.26 0.27 0.31

Amryt Pharma Inventory Turnover Calculation

Amryt Pharma's Inventory Turnover for the fiscal year that ended in Dec. 2021 is calculated as

Inventory Turnover (A: Dec. 2021 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2021 ) / ((Total Inventories (A: Dec. 2020 ) + Total Inventories (A: Dec. 2021 )) / count )
=106.119 / ((40.992 + 115.769) / 2 )
=106.119 / 78.3805
=1.35

Amryt Pharma's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

Inventory Turnover (Q: Sep. 2022 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Sep. 2022 ) / ((Total Inventories (Q: Jun. 2022 ) + Total Inventories (Q: Sep. 2022 )) / count )
=33.703 / ((124.185 + 90.238) / 2 )
=33.703 / 107.2115
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amryt Pharma  (NAS:AMYT) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Amryt Pharma's Days Inventory for the three months ended in Sep. 2022 is calculated as:

Days Inventory =Average Total Inventories (Q: Sep. 2022 )/Cost of Goods Sold (Q: Sep. 2022 )*Days in Period
=107.2115/33.703*365 / 4
=290.27

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Amryt Pharma's Inventory to Revenue for the quarter that ended in Sep. 2022 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=107.2115 / 61.126
=1.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Amryt Pharma Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Amryt Pharma (Amryt Pharma) Business Description

Traded in Other Exchanges
N/A
Address
196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).